Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...
healthday on MSN1h
Age Differences Seen in Efficacy of Type 2 Diabetes TreatmentsAge differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...
This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...
Wesper, a leader in advanced home sleep apnea testing (HSAT), is transforming how obesity and sleep apnea are managed by integrating groundbreaking biometric sleep data with metabolic health ...
GlobalData on MSN13h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
Amy Schumer is getting candid about her unpleasant experience on the weight loss drug Ozempic. The comedian and actress, 43, ...
Hosted on MSN19h
Discovery of neurons responsible for appetite 🧠Researchers have identified a group of brain cells in mice that play a key role in regulating appetite. These neurons, ...
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback